Squalene synthase inhibition: A novel target for the management of dyslipidemia

被引：37

作者：

Davidson M.H. ^{[1
]}

机构：

[1] Radiant Research, Chicago, IL 60610

来源：

Current Atherosclerosis Reports | 2007年 / 9卷 / 1期

关键词：

Statin; Atorvastatin; Squalene; Rosuvastatin; Ezetimibe;

D O I：

10.1007/BF02693932

中图分类号：

学科分类号：

摘要：

A new class of compounds, known as squalene synthase inhibitors, has recently reached phase III clinical trials and may provide another therapeutic option for clinicians to improve risk management of low-density lipoprotein cholesterol (LDL-C). The clinical need for another LDL-C-lowering therapy is evident by the inability to achieve an LDL-C target of less than 70 mg/dL in the majority of very high-risk patients on statin monotherapy. Human clinical trial data with TAK-475, a novel and potent inhibitor of squalene synthase, have not yet been published. Copyright © 2007 by Current Medicine Group LLC.

引用

页码：78 / 80

页数：2

共 23 条

[1]

Grundy S.M., Cleeman J.I., Merz C.N., Et al., Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines, Circulation, 110, pp. 227-239, (2004)

[2]

Smith Jr. S.C., Allen J., Blair S.N., Et al., AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update

[3]

endorsed by the National Heart, Lung, and Blood Institute, Circulation, 113, pp. 2363-2372, (2006)

[4]

LaRosa J.C., Grundy S.M., Waters D.D., Et al., Intensive lipid lowering with atorvastatin in patients with stable coronary disease, N Engl J Med, 352, pp. 1425-1435, (2005)

[5]

Pedersen T.R., Faergeman O., Kastelein J.J., Et al., High-dose atorvastatin vs usual-dose simvastatin for secondary prevention after myocardial infarction: The IDEAL study: A randomized controlled trial, JAMA, 294, pp. 2437-2445, (2005)

[6]

Davidson M.H., Maki K.C., Pearson T.A., Et al., Results of the National Cholesterol Education (NCEP) Program Evaluation ProjecT Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations, Am J Cardiol, 96, pp. 556-563, (2005)

[7]

Nissen S.E., Nicholls S.J., Sipahi I., Et al., Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: The ASTEROID trial, JAMA, 295, pp. 1556-1565, (2006)

[8]

Robinson J.G., Davidson M.H., Combination therapy with ezetimibe and simvastatin to achieve aggressive LDL reduction, Expert Rev Cardiovasc Ther, 4, pp. 461-476, (2006)

[9]

Davidson M.H., Robinson J.G., Lipid-lowering effects of statins: A comparative review, Expert Opin Pharmacother, 7, pp. 1701-1714, (2006)

[10]

Soma M.R., Corsini A., Paoletti R., Cholesterol and mevalonic acid modulation in cell metabolism and multiplication, Toxicol Lett, 64-65, pp. 1-15, (1992)

← 1 2 3 →